Lactobacillus gasseri 用于 Gastroesophageal Reflux Disease (GERD)
DEmerging evidence from Japanese studies. May reduce acid-related symptoms. Not yet replicated in Western populations.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dgerd';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
结论
Emerging evidence from Japanese studies. May reduce acid-related symptoms. Not yet replicated in Western populations.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
效果: None
None
研究人群: patients with IBS from 32 RCTs evaluating 10 probiotic strains
In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None
vs: H. pylori infection without lactobacilli
Outcome: ADAM17, HBEGF, TGF-alpha expression
效果: None
None
研究人群: AGS gastric epithelial cells and mouse model
In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml
vs: None
Outcome: Inflammatory markers
效果: None
None
研究人群: None
Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None
vs: None
Outcome: Inflammatory markers
效果: None
None
研究人群: Cancer patients
In Vitro
Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability …
Dose: None
vs: None
Outcome: inflammation markers
效果: None
None
研究人群: Mice
Case-Control
n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None
vs: None
Outcome: Oral/gastric microbiome associations with IM
效果: None
None
研究人群: Gastric intestinal metaplasia cases and matched controls
Key Statistics
3
研究数量
300
受试者
↑
Positive
D
等级
Referenced Papers
Journal of clinical …
2026
International journal of …
2025
Microbial pathogenesis
2024
8 次引用
Helicobacter
2024
5 次引用
International journal of …
2023
9 次引用
International journal of …
2022
59 次引用
BMC microbiology
2022
28 次引用
Food & function
2022
19 次引用
Probiotics and antimicrobial …
2021
30 次引用
Comparative immunology, microbiology …
2019
72 次引用
BMJ open gastroenterology
2019
14 次引用
Digestion
2017
67 次引用
Gastroenterology research and …
2016
38 次引用
Helicobacter
2015
26 次引用
PloS one
2014
171 次引用
Frontiers in microbiology
2014
78 次引用
Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health.
Review
FEMS microbiology reviews
2013
196 次引用
Journal of food …
2012
56 次引用
Journal of clinical …
2012
37 次引用
Letters in applied …
2010
126 次引用
Journal of medicinal …
2010
19 次引用
Probiotics and antimicrobial …
2010
9 次引用
Helicobacter
2009
48 次引用
Cellular microbiology
2006
50 次引用
Letters in applied …
2006
26 次引用
Journal of gastroenterology …
2003
77 次引用
The Journal of …
2001
309 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 1-10 billion CFU/day
- gerdsupport:
- 1-5 billion CFU/day
- hpylorisupport:
- 100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks
上限： Well-tolerated up to 10 billion CFU/day in clinical trials
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| 50 μg/ml | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Neutral | 178 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
最佳服用时间： Before meals or with meals; yogurt form taken with food
Safety & Side Effects
已报告的副作用
- ⚠ Mild gas during initial use
- ⚠ Occasional loose stools
- ⚠ Rare abdominal discomfort
- ⚠ Very rare: bacteremia in immunocompromised individuals
已知相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Proton pump inhibitors (altered gastric pH may affect colonization)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
可耐受最高摄入量： Well-tolerated up to 10 billion CFU/day in clinical trials
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Lactobacillus gasseri help with Gastroesophageal Reflux Disease (GERD)?
Based on 3 studies with 300 participants, there is preliminary evidence that needs more research that Lactobacillus gasseri may support Gastroesophageal Reflux Disease (GERD) management. Our evidence grade is D (Very Early Research).
How much Lactobacillus gasseri should I take for Gastroesophageal Reflux Disease (GERD)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus gasseri?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus gasseri and Gastroesophageal Reflux Disease (GERD)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 3 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 Gastroesophageal Reflux Disease (GERD)
Lactobacillus gasseri 用于其他健康状况
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。